Cullinan Therapeutics (NASDAQ:CGEM) Stock Rating Reaffirmed as Buy by HC Wainwright

Cullinan Therapeutics (NASDAQ:CGEM)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report issued on Friday, Benzinga reports. They currently have a $35.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 137.37% from the stock’s current price. HC Wainwright also issued estimates for Cullinan Therapeutics’ Q1 2027 earnings at ($0.95) EPS, Q2 2027 earnings at ($0.96) EPS, Q3 2027 earnings at ($0.98) EPS, Q4 2027 earnings at ($1.00) EPS and FY2027 earnings at ($3.89) EPS.

Other equities analysts have also issued reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Cullinan Therapeutics in a research report on Wednesday, July 8th. BTIG Research reaffirmed a “buy” rating and set a $40.00 target price on shares of Cullinan Therapeutics in a report on Friday, September 25th. Wedbush lifted their target price on shares of Cullinan Therapeutics from $39.00 to $42.00 and gave the company an “outperform” rating in a report on Thursday, August 13th. Wall Street Zen lowered shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, September 13th. Finally, TD Cowen raised shares of Cullinan Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cullinan Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $33.71.

Cullinan Therapeutics Stock Performance

CGEM stock traded up $0.22 during trading on Friday, reaching $14.75. The company had a trading volume of 161,428 shares, compared to its average volume of 900,558. The firm has a 50-day simple moving average of $19.56 and a 200-day simple moving average of $16.73. The company has a market cap of $948.99 million, a price-to-earnings ratio of -4.76 and a beta of -0.04. Cullinan Therapeutics has a twelve month low of $5.68 and a twelve month high of $23.19.

Cullinan Therapeutics (NASDAQ:CGEM) last released its earnings results on Thursday, August 6th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.01). Sell-side analysts expect that Cullinan Therapeutics will post -3.08 earnings per share for the current year.

Insider Transactions at Cullinan Therapeutics

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 8,000 shares of Cullinan Therapeutics stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $21.57, for a total transaction of $172,560.00. Following the sale, the insider owned 158,844 shares of the company’s stock, valued at $3,426,265.08. The trade was a 4.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders have sold 46,000 shares of company stock worth $922,920. Insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Cullinan Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Elmind Capital LP acquired a new position in shares of Cullinan Therapeutics during the 2nd quarter valued at about $12,564,900. BlackRock Inc. acquired a new position in shares of Cullinan Therapeutics during the 2nd quarter valued at about $95,289,000. Engineers Gate Manager LP boosted its position in shares of Cullinan Therapeutics by 130.9% during the 2nd quarter. Engineers Gate Manager LP now owns 153,050 shares of the company’s stock valued at $2,787,000 after acquiring an additional 86,762 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Cullinan Therapeutics during the 2nd quarter valued at about $3,114,000. Finally, Blue Owl Capital Holdings LP acquired a new position in shares of Cullinan Therapeutics during the 2nd quarter valued at about $28,039,000. Institutional investors and hedge funds own 86.31% of the company’s stock.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer and autoimmune diseases. The company uses a portfolio-based approach to advance targeted therapies and immune-modulating treatments intended to address significant unmet medical needs.

Cullinan’s pipeline includes zovoltamab brengitecan (CLN-978), an investigational CD19-directed T-cell engager being studied in B-cell malignancies and autoimmune conditions, and CLN-619, an investigational antibody designed to target MICA and MICB proteins and stimulate anti-tumor immune responses.